Aligos Therapeutics, Inc. (NASDAQ:ALGS) Brief Interest Update
Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get a rating) was the target of a significant decline in short-term interest in June. As of June 30, there was short interest totaling 2,230,000 shares, a decrease of 22.0% from the June 15 total of 2,860,000 shares. Currently, 10.0% of the stock’s shares are sold short. Based on an average daily trading volume of 329,400 shares, the day-to-cover ratio is currently 6.8 days.
Hedge funds weigh on Aligos Therapeutics
Major investors have recently changed their stake in the company. Ensign Peak Advisors Inc bought a new position in shares of Aligos Therapeutics in Q4 for a value of approximately $87,000. ProShare Advisors LLC bought a new position in shares of Aligos Therapeutics in Q4 for a value of approximately $121,000. Virtus ETF Advisers LLC increased its equity stake in Aligos Therapeutics by 108.5% in Q4. Virtus ETF Advisers LLC now owns 14,209 shares of the company worth $169,000 after purchasing an additional 7,395 shares during the period. Denali Advisors LLC bought a new stock position in Aligos Therapeutics in Q1 worth approximately $34,000. Finally, Wedmont Private Capital bought a new position in shares of Aligos Therapeutics in the 2nd quarter for a value of approximately $25,000. 70.21% of the shares are currently held by hedge funds and other institutional investors.
Aligos Therapeutics grew by 1.9%
Shares of NASDAQ:ALGS opened at $1.60 on Thursday. The stock’s 50-day moving average price is $1.31 and its two-hundred-day moving average price is $2.19. Aligos Therapeutics has a 12-month low of $1.03 and a 12-month high of $17.97. The company has a market capitalization of $68.31 million, a price-earnings ratio of -0.48 and a beta of 2.78.
Therapeutic Aligos (NASDAQ:ALGS – Get a rating) last released its quarterly results on Wednesday, May 4. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.66) by ($0.18). The company recorded revenue of $2.57 million during the quarter. Aligos Therapeutics posted a negative return on equity of 75.34% and a negative net margin of 2,263.64%. During the same quarter last year, the firm posted ($0.74) earnings per share. As a group, research analysts expect Aligos Therapeutics to post earnings per share of -2.93 for the current fiscal year.
Analysts set new price targets
ALGS has been the subject of a number of analyst reports. Piper Sandler downgraded Aligos Therapeutics from an “overweight” rating to a “neutral” rating and lowered its price target for the company from $15.00 to $4.00 in a Wednesday, March 23 research note. SVB Leerink downgraded Aligos Therapeutics from an “outperforming” rating to a “market performing” rating in a Thursday, May 5 research note. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on Aligos Therapeutics shares in a Wednesday, June 8 research note. Four equity research analysts gave the stock a hold rating and one gave the stock a buy rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.
Aligos Therapeutics Company Profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, an oligonucleotide polymer inhibitor of s antigen transport which is in a phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat HCB.
Get news and reviews for Aligos Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Aligos Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.